Holen Sie sich die Stockscreener-App
259.40
5.71%
-16.24
Schlusskurs vom Vortag:
$275.64
Offen:
$267.6
24-Stunden-Volumen:
258.69K
Relative Volume:
0.88
Marktkapitalisierung:
$7.59B
Einnahmen:
$290.51M
Nettoeinkommen (Verlust:
$89.16M
KGV:
86.76
EPS:
2.99
Netto-Cashflow:
$119.18M
1W Leistung:
-5.35%
1M Leistung:
-7.92%
6M Leistung:
+74.44%
1J Leistung:
+45.00%
1-Tages-Spanne:
$259.00
$270.00
1-Wochen-Bereich:
$259.00
$277.03
52-Wochen-Spanne:
$122.80
$298.30
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
259.77 | 8.06B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.16 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.19 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
757.10 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.11 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.14 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech (KRYS) Is Up 5.6% After Stronger 2025 Profitability And EPS Growth Has The Bull Case Changed? - Sahm
Guggenheim Lifts PT on Krystal Biotech (KRYS) to $284 From $224 - Yahoo Finance
Krystal Biotech director Janney sells shares worth $10.1 million - Investing.com
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 700 Shares - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Director Daniel Janney Sells 37,895 Shares - MarketBeat
Daniel Janney Sells 7,741 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech Director Janney Daniel Sells Over $16 Million in Company Stock - TradingView
KRYS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Vanguard Group Inc. Cuts Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Assessing Krystal Biotech (KRYS) Valuation After Earnings Beat And Profitability Milestone - simplywall.st
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Krystal Biotech (NASDAQ:KRYS) Given New $284.00 Price Target at Guggenheim - MarketBeat
Guggenheim Raises Price Target for Krystal Biotech (KRYS) to $284 | KRYS Stock News - GuruFocus
Krystal Biotech slips more than 2% even after Q4 earnings and revenue top estimates - MSN
Risk On: Can Krystal Biotech Inc weather a recessionJuly 2025 Market Mood & Growth Focused Entry Reports - baoquankhu1.vn
Insider Unloading: Dino A Rossi Sells Options, Realizes $5.04M - Benzinga
Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference - Bitget
Krystal Biotech’s KB707 RMAT Win Opens New Lung Cancer Chapter - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock - MarketBeat
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million - Investing.com
Krystal Biotech (KRYS) director Rossi sells shares worth $4.95 million By Investing.com - Investing.com India
Director at Krystal Biotech (NASDAQ: KRYS) sells 18,950 shares - Stock Titan
Krystal Biotech, Inc. (KRYS) Stock Analysis: An Investor's Guide To A Promising 17% Upside - DirectorsTalk Interviews
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 - Yahoo Finance
Jefferies Raises its Price Target on Krystal Biotech, Inc. (KRYS) to $371 and Maintains a Buy Rating - Finviz
Aug EndMonth: What is the long term forecast for Giftify Inc stockInsider Selling & Expert Curated Trade Ideas - baoquankhu1.vn
Analysts Offer Predictions for Krystal Biotech Q2 Earnings - MarketBeat
Krystal Biotech, Inc. $KRYS Shares Sold by Aberdeen Group plc - MarketBeat
Krystal Biotech (NASDAQ:KRYS) Trading Down 6.9%Here's Why - MarketBeat
HC Wainwright Forecasts Krystal Biotech Q1 Earnings - MarketBeat
Why Analysts See Krystal Biotech (KRYS) Story Shifting After New Data And Target Resets - Yahoo Finance
Krystal Biotech (KRYS): Citigroup Raises Price Target to $371 | - GuruFocus
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Cogent Biosciences (COGT) - The Globe and Mail
Reassessing Krystal Biotech (KRYS) After Strong 1-Year Rally And Vyjuvek Pipeline Focus - Yahoo Finance
Krystal Biotech stock reaches all-time high at 296.78 USD By Investing.com - Investing.com Australia
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark - Finviz
Buy Rating on Krystal Biotech Driven by Vyjuvek’s Global Momentum and Upside from Enhanced NK and Corneal Abrasion Pipeline - TipRanks
Krystal Biotech, Inc. (NASDAQ:KRYS) Q4 2025 Earnings Call Transcript - Insider Monkey
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $323.00 - MarketBeat
KRYS: Chardan Capital Raises Price Target to $323.00, Maintains Buy Rating | KRYS Stock News - GuruFocus
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts - Benzinga
Krystal Biotech targets global VYJUVEK expansion with Italy launch in H2 2026 while maintaining 90%–95% gross margin outlook - MSN
MSN Money - MSN
Readystate Asset Management LP Sells 77,631 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
CSL licenses Eli Lilly's clazakizumab to cut cardiac risk in end-stage kidney disease - AOL.com
Krystal Biotech (NASDAQ:KRYS) Hits New 1-Year High After Earnings Beat - MarketBeat
Decoding Krystal Biotech Inc (KRYS): A Strategic SWOT Insight - GuruFocus
KRYS Krystal Biotech Feb 17, 2026 Jefferies Maintains Buy - Meyka
Krystal Biotech Earnings Call Highlights Profitable Growth - TipRanks
Krystal Biotech (KRYS) Reports Strong Q4 Revenue and Expansion P - GuruFocus
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):